TABLE 3.
The univariate and multivariate analysis of ORR, DCR, PFS and OS
| Variable | Objective response rate | Disease control rate | Progression‐free survival | Overall survival | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| OR (95% CI) | p‐value | OR (95% CI) | p‐value | OR (95% CI) | p‐value | OR (95% CI) | p‐value | HR (95% CI) | p‐value | HR (95% CI) | p‐value | HR (95% CI) | p‐value | HR (95% CI) | p‐value | |
| Age (years) | 1.06 (0.97–1.16) | 0.228 | 1.03 (0.95–1.11) | 0.499 | 0.97 (0.94–1.00) | 0.075 | 0.98 (0.94–1.02) | 0.263 | ||||||||
| ECOG PS (1 vs 0) | 4.24 (0.87–20.64) | 0.111 | 1.06 (0.38–2.92) | 0.916 | 2.35 (1.26–4.41) | 0.007 | 1.45 (0.81–2.61) | 0.211 | 1.68 (0.83–3.4) | 0.150 | ||||||
| Smoking (yes vs no) | 2.05 (0.51–8.15) | 0.474 | 5.33 (1.55–18.3) | 0.011 | 4.98 (1.20–20.7) | 0.027 | 0.53 (0.28–0.99) | 0.046 | 0.65 (0.34–1.22) | 0.181 | 1.01 (0.55–1.86) | 0.980 | ||||
| Gender (male vs. female) | 1.22 (0.13–11.81) | 1.000 | 0.55 (0.09–3.53) | 0.866 | 1.41 (0.57–3.48) | 0.454 | 1.16 (0.44–3.07) | 0.763 | ||||||||
| Disease stage (locally advanced vs. metastatic) | 1.70 (0.14–20.07) | 0.674 | 0.57 (0.05–6.53) | 0.647 | 0.82 (0.23–2.94) | 0.767 | 0.89 (0.19–3.93) | 0.850 | ||||||||
| Previous radiotherapy (yes vs. no) | 0.56 (0.18–1.75) | 0.313 | 1.56 (0.56–4.30) | 0.393 | 0.95 (0.58–1.60) | 0.857 | 1.03 (0.59–1.82) | 0.908 | ||||||||
| Previous surgery (yes vs. no) | 2.98 (0.94–9.49) | 0.058 | 1.50 (0.37–5.97) | 0.569 | 3.04 (1.13–8.20) | 0.026 | 1.32 (0.39–4.44) | 0.659 | 0.57 (0.35–0.94) | 0.029 | 0.94 (0.53–1.65) | 0.823 | 0.52 (0.29–0.92) | 0.026 | 0.58 (0.32–1.04) | 0.069 |
| Prior chemo‐lines (0–1 vs ≥2) | 1.97 (0.56–6.93) | 0.441 | 1.16 (0.43–3.12) | 0.765 | 0.86 (0.51–1.45) | 0.577 | 0.49 (0.27–0.88) | 0.018 | 1.31 (0.69–2.46) | 0.410 | ||||||
| PD‐L1 TPS (≥vs. <10%) | 3.43 (1.01–11.68) | 0.042 | 2.83 (0.71–11.32) | 0.142 | 3.5 (1.19–10.31) | 0.020 | 5.3 (1.4–19.35) | 0.014 | 0.47 (0.28–0.79) | 0.004 | 0.44 (0.26–0.77) | 0.004 | 0.96 (0.54–1.71) | 0.883 | ||
| Baseline NLR (≥4 vs.<4) | 0.18 (0.05–0.70) | 0.018 | 0.21 (0.05–0.86) | 0.030 | 0.58 (0.22–1.51) | 0.265 | 1.79 (1.07–3.00) | 0.026 | 1.69 (0.97–2.94) | 0.065 | 2.28 (1.24–4.17) | 0.008 | 2.50 (1.33–4.68) | 0.004 | ||
| HLA‐I (Homo vs. Hetero) | Not calculated a | 0.056 | Not calculated a | 0.999 | 0.09 (0.01–0.73) | 0.018 | 0.06 (0.01–0.64) | 0.020 | 3.37 (1.35–8.46) | 0.010 | 2.48 (1.20–5.14) | 0.015 | 3.97 (1.56–10.12) | 0.004 | 2.56 (1.26–5.22) | 0.009 |
Abbreviations: CI, confidence interval; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; HLA‐I, human leukocyte antigen class I; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio; OR, odds ratio; ORR, overall response rate; OS, overall survival; PD‐L1, programmed death receptor ligand 1; PFS, progression‐free survival; TPS, tumor proportion score.
a
Not calculated：: OR could not be calculated when the objective response rate was 0% in patients with poor factors.